icon-folder.gif   Conference Reports for NATAP  
 
  IDWeek
October 3 -7, 2018
San Francisco, CA
Back grey_arrow_rt.gif
 
 
 
A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Na´ve Adults at Week 96
 
 
  Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco
 
David Wohl,1 Yazdan Yazdanpanah,2 Axel Baumgarten,3 Amanda Clarke,4 Melanie A. Thompson,5 Cynthia Brinson,6 Debbie Hagins,7 Moti N. Ramgopal,8 Andrea Antinori,9 Xuelian Wei,10 Kirsten White,10 Sean Collins,10 Andrew Cheng,10 Hal Martin10
 
1University of North Carolina at Chapel Hill, NC; 2Hopital Bichat Claude Bernard, Paris, France; 3Zentrum fur Infektiologie Berlin Prenzlauer Berg, Berlin, Germany; 4Royal Sussex County Hospital, Brighton, UK; 5AIDS Research Consortium of Atlanta, GA; 6Central Texas Clinical Research, Austin, TX; 7Georgia Department of Public Health, Chatham Care Center, Savannah, GA; 8Midway Immunology Center, Ft. Pierce, FL; 9National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy; 10Gilead Sciences, Inc., Foster City, CA

1004181

1004182

1004183

1004184

1004185

1004186

1004187

1004188